Advertisement
Advertisement
U.S. markets close in 3 hours 9 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Mustang Bio, Inc. (MBIO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.1913-0.0987 (-4.31%)
As of 12:50PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close2.2900
Open2.3100
Bid2.2300 x 1200
Ask2.2400 x 3000
Day's Range2.1900 - 2.3100
52 Week Range2.1900 - 5.2200
Volume521,377
Avg. Volume1,040,385
Market Cap200.29M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MBIO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Mustang Bio, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/06/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Mustang Bio to Participate in Chardan’s Virtual 5th Annual Genetic Medicines Conference

    WORCESTER, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, and members of the Mustang Leadership Team will participate in a fireside chat at Chardan’s Virtual 5th Annua

  • GlobeNewswire

    Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

    Christine Brown, Ph.D., of City of Hope will present at the First Annual Conference on CNS Clinical Trials Co-sponsored by SNO and ASCO and the AACR Virtual Special Conference: Brain CancerWORCESTER, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, tod

  • GlobeNewswire

    Mustang Bio to Participate in Three September 2021 Investor Conferences

    WORCESTER, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in September 2021. Details of the events are as follow

Advertisement
Advertisement